Handa Pharmaceuticals, Inc. (TPEX: 6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.70
-1.30 (-2.45%)
Dec 19, 2024, 2:56 PM CST
-73.49%
Market Cap 7.70B
Revenue (ttm) 972.97M
Net Income (ttm) 452.32M
Shares Out 141.20M
EPS (ttm) 3.24
PE Ratio 16.81
Forward PE 3.41
Dividend 1.00 (1.83%)
Ex-Dividend Date n/a
Volume 184,103
Open 52.50
Previous Close 53.00
Day's Range 50.80 - 52.50
52-Week Range 49.90 - 200.00
Beta 1.31
Analysts n/a
Price Target n/a
Earnings Date Dec 26, 2024

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-0... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.